Part 4- The Major Neurobiological Theories of Addiction

Mohamad-Ali Salloum, PharmD • April 3, 2026

Share

  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button
đź§ 

Understanding addiction means understanding how multiple brain systems work — and sometimes malfunction — together.

Addiction is not caused by a single biological mechanism. Instead, decades of research indicate that different brain systems—reward, stress, learning, and motivation—interact to shape the development of compulsive drug use and relapse. Modern reviews emphasize that the major neurobiological theories of addiction should not be viewed as competing explanations but rather as complementary frameworks that illuminate different facets of this chronic disorder. This article provides a clear, evidence‑based overview of the core theories shaping our modern understanding of addiction.


1. Opponent-Process Theory: The Shift From Pleasure to Relief

The Opponent-Process Theory proposes that each drug-induced pleasurable effect is followed by an opposing negative emotional state. Over time, the positive response weakens, while the negative rebound intensifies, driving continued substance use to avoid discomfort rather than to seek pleasure. A 2024 comprehensive review highlights this as one of the earliest models explaining the emotional dysregulation seen in addiction and how chronic exposure shifts the brain’s hedonic balance.

đź§© In simple terms: The drug gradually stops producing a strong “high,” but the “low” becomes stronger — so the person uses to escape the negative state.

2. Dopamine Dysregulation and Reward Deficit Models

Many addiction theories converge on the central role of dopamine. Early drug use overstimulates the mesocorticolimbic dopamine pathway, but chronic exposure leads to neuroadaptive changes: dopamine receptors downregulate, natural rewards lose their impact, and drug-related cues gain excessive motivational power. A 2025 chapter on the neurobiology of substance use disorders describes this process as hedonic allostasis, in which the brain’s reward baseline shifts downward and stress levels rise.

đź§© In simple terms: Natural pleasures no longer feel rewarding, and the drug becomes the main source of dopamine.

3. Incentive Sensitization Theory: When Wanting Becomes Pathological

The Incentive Sensitization Theory (IST) distinguishes between “liking” (pleasure) and “wanting” (motivational drive). According to IST, repeated drug exposure sensitizes the dopamine systems responsible for incentive motivation, causing intense craving even as the drug becomes less pleasurable. A major 2025 review summarizes decades of evidence showing that sensitization persists long after drug cessation, explains heightened vulnerability to relapse, and applies to both substance and behavioral addictions.

A 2024 update further confirms IST’s relevance to substances that produce minimal withdrawal and its ability to explain relapse after long periods of abstinence.

đź§© In simple terms: You may stop liking the drug, but your brain continues to want it intensely because its “wanting” circuits have been sensitized.

4. Habit and Compulsion Theories: When Behavior Becomes Automatic

Habit‑based theories propose that addiction reflects a shift from goal‑directed action to stimulus–response automaticity. Over repeated use, drug‑seeking transitions from voluntary decision‑making (prefrontal cortex) to habitual responding (dorsal striatum). A 2024 review highlights individual differences — such as “sign‑tracking,” in which people attribute strong motivational value to cues — as key factors in vulnerability to compulsive drug use.

🧩 In simple terms: At first the person chooses the drug; eventually, environmental cues automatically trigger drug‑seeking, even against conscious intentions.

5. Allostasis Theory: Addiction as a Chronic Stress Disorder

Allostasis describes how the brain maintains stability by adjusting internal set points. In addiction, repeated drug use forces the reward‑stress system into a new pathological baseline. Evidence shows that repeated intoxication produces reward deficits, while withdrawal activates stress circuits such as the amygdala and hypothalamus. Over time, individuals use substances not to feel good, but to relieve an increasingly negative emotional state.

đź§© In simple terms: The brain adapts to repeated drug exposure by lowering its reward baseline and increasing stress, making the person feel chronically worse without the drug.

6. The Three-Stage Neurocircuitry Model of Addiction

Neuroimaging research supports a cyclical model of addiction involving three interconnected stages:

Binge/Intoxication
Dopamine and opioid surges in the nucleus accumbens reinforce drug‑taking.

Withdrawal/Negative Affect
Stress‑related regions (amygdala, hypothalamus) generate dysphoria, irritability, and anxiety.

Preoccupation/Anticipation
Dysfunction in the prefrontal cortex and insula impairs self‑control and heightens craving, increasing relapse risk.

A psychoradiology review (2022–2024) documents the distinct circuits involved at each stage and their relevance for targeted treatment approaches.

đź§© In simple terms: Addiction cycles through reward, stress, and craving — each stage activating different brain regions.

7. Integrating the Theories: A Multifactorial View

A 2024 review emphasizes that all major neurobiological theories point toward a shared conclusion: addiction emerges from the interaction between biological vulnerability, learning processes, environmental influence, and long‑term neuroadaptation. No single theory can account for addiction on its own; together they create a comprehensive understanding of both its development and persistence.

đź§© In simple terms: Addiction is too complex for one explanation. These models together provide a clearer, more complete picture.

✅ Mini‑Exercise: Test Your Understanding

  1. Describe how the Incentive Sensitization Theory explains relapse even after long abstinence.
  2. Which neural system takes over as drug use becomes habitual, and why is this shift important?
  3. Compare the Opponent‑Process Theory and the Allostasis Theory in terms of emotional states during addiction.
  4. Provide an example of a stimulus–response habit that could contribute to compulsive drug use.
  5. Which theory best explains why drug cues feel overwhelmingly powerful, and what neural mechanism underlies this?

Scroll up to review the sections and evaluate your answers.


References:

  1. FerrerPérez C, MontagudRomero S, BlancoGandía MC. Neurobiological Theories of Addiction: A Comprehensive Review. Psychoactives. 2024;3(1):3547. 1 
  2. Su H, Ye T, Cao S, Hu C. Understanding the shift to compulsion in addiction: insights from personality traits, social factors, and neurobiology. Front Psychol. 2024;15. 5 
  3. Robinson TE, Berridge KC. The IncentiveSensitization Theory of Addiction 30 Years On. Annu Rev Psychol. 2025. 3 
  4. Palombo P. Neurobiology of Substance Use Disorders. In: Neuropsychology and Substance Use Disorders. Springer; 2025. 2 
  5. Fang Y, Sun Y, Liu Y, et al. Neurobiological mechanisms and related clinical treatment of addiction: a review. Psychoradiology. 2022;2(4):180189. 6 
  6. Robinson TE, Berridge KC. The IncentiveSensitization Theory of Addiction 30 years on. CLBB NeuroLaw Library. 2024. 4 





List of Services

    • Slide title

      Write your caption here
      Button
    • Slide title

      Write your caption here
      Button
    • Slide title

      Write your caption here
      Button
    • Slide title

      Write your caption here
      Button

    ABOUT THE AUTHOR

    Mohamad-Ali Salloum, PharmD

    Mohamad Ali Salloum LinkedIn Profile

    Mohamad-Ali Salloum is a Pharmacist and science writer. He loves simplifying science to the general public and healthcare students through words and illustrations. When he's not working, you can usually find him in the gym, reading a book, or learning a new skill.

    Share

    Recent articles:

    By Mohamad-Ali Salloum, PharmD May 19, 2026
    Stuck in your head? Discover why overthinking feels productive, how it sabotages your performance, and simple ways to shift into real action.
    By Mohamad-Ali Salloum, PharmD May 17, 2026
    References: Wood W, Quinn JM, Kashy DA. Habits in everyday life: Thought, emotion, and action. J Pers Soc Psychol . 2002;83(6):1281–1297. Wood W, Neal DT. The habitual consumer. J Consum Psychol . 2009;19(4):579–592. Neal DT, Wood W, Labrecque JS, Lally P. How do habits guide behavior? Perceived and actual triggers of habits in daily life. J Exp Soc Psychol . 2012;48(2):492–498. Wood W, Mazar A, Neal DT. Habits and goals in human behavior: Separate but interacting systems. Perspect Psychol Sci . 2021;16(1):1–16. Graybiel AM. Habits, rituals, and the evaluative brain. Annu Rev Neurosci . 2008;31:359–387. Smith KS, Graybiel AM. Habit formation. Dialogues Clin Neurosci . 2016;18(1):33–43. Yin HH, Knowlton BJ. The role of the basal ganglia in habit formation. Nat Rev Neurosci . 2006;7(6):464–476. Graybiel AM. The basal ganglia and chunking of action repertoires. Neurobiol Learn Mem . 1998;70(1–2):119–136. Schultz W. Dopamine reward prediction error coding. Dialogues Clin Neurosci . 2016;18(1):23–32. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science . 1997;275(5306):1593–1599. Nasser HM, Calu DJ, Schoenbaum G, Sharpe MJ. The dopamine prediction error: Contributions to associative models of reward learning. Front Psychol . 2017;8:244. Kahnt T, Schoenbaum G. The curious case of dopaminergic prediction errors and learning associative information beyond value. Nat Rev Neurosci . 2025;26:169–178. Lally P, van Jaarsveld CHM, Potts HWW, Wardle J. How are habits formed: Modelling habit formation in the real world. Eur J Soc Psychol . 2010;40(6):998–1009. American Psychological Association. Harnessing the power of habits. Monitor Psychol . 2020;51(8):78–83.
    By Mohamad-Ali Salloum, PharmD May 15, 2026
    References: Baddeley A. Working memory: theories, models, and controversies. Annu Rev Psychol . 2012;63:1–29. Chai WJ, Abd Hamid AI, Malin Abdullah J. Working memory from the psychological and neurosciences perspectives: a review. Front Psychol . 2018;9:401. Rogers RD, Monsell S. Costs of a predictable switch between simple cognitive tasks. J Exp Psychol Gen . 1995;124(2):207–231. Rubinstein JS, Meyer DE, Evans JE. Executive control of cognitive processes in task switching. J Exp Psychol Hum Percept Perform . 2001;27(4):763–797. Garner KG, Dux PE. Knowledge generalization and the costs of multitasking. Nat Rev Neurosci . 2023;24:98–112. Zhou X, Lei X. Wandering minds with wandering brain networks. Neurosci Bull . 2018;34(6):1017–1028. Sorella S, Crescentini C, Matiz A, et al. Resting‑state default mode network variability predicts spontaneous mind‑wandering. Front Hum Neurosci . 2025;19:1515902. Sweller J. Cognitive load during problem solving: effects on learning. Cogn Sci . 1988;12(2):257–285. 
    By Mohamad-Ali Salloum, PharmD May 13, 2026
    Why do we procrastinate even when tasks matter most? Discover the emotional roots of procrastination and how to stop
    By Mohamad-Ali Salloum, PharmD May 11, 2026
    Confidence and self-esteem are often confused but are psychologically distinct. Learn how they differ, how each develops, and why understanding both matters for real growth.
    By Mohamad-Ali Salloum, PharmD May 9, 2026
    Confidence isn’t about eliminating fear—it’s about acting despite it. Discover how courage, discomfort, and psychological growth build real confidence over time.
    By Mohamad-Ali Salloum, PharmD May 7, 2026
    References: McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med . 2014;371(11):993–1004. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med . 2007;357:2109–2122. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med . 2008;358:1431–1443. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med . 2008;358:2545–2559. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med . 1991;324:781–788. Packer M, Anker SD, Butler J, et al. Effect of empagliflozin on cardiovascular and renal outcomes. N Engl J Med . 2020;383:1413–1424. Ioannidis JPA. Surrogate endpoints in clinical trials: are we being misled? BMJ . 2013;346:f314.
    By Mohamad-Ali Salloum, PharmD May 4, 2026
    References: Wager TD, Atlas LY. The neuroscience of placebo effects: connecting context, learning and health. Nat Rev Neurosci . 2015;16(7):403‑18. Frisaldi E, Shaibani A, Benedetti F, Pagnini F. Placebo and nocebo effects associated with pharmacological interventions: an umbrella review. BMJ Open . 2023;13:e077243. Colloca L, Finniss D. Nocebo effects, patient‑clinician communication, and therapeutic outcomes. JAMA . 2012;307(6):567‑8. Howard JP, Wood FA, Finegold JA, et al. Side effect patterns in a blinded, randomized trial of statin, placebo, and no treatment. N Engl J Med . 2021;385(23):2180‑9. Penson PE, Mancini GBJ, Toth PP, et al. Introducing the “drucebo” effect in statin therapy. J Cachexia Sarcopenia Muscle . 2018;9(6):1023‑33. Barnes K, Faasse K, Geers AL, et al. Can positive framing reduce nocebo side effects? Front Pharmacol . 2019;10:167. Caliskan EB, Bingel U, Kunkel A. Translating knowledge on placebo and nocebo effects into clinical practice. Pain Rep . 2024;9(2):e1142. von Wernsdorff M, Loef M, Tuschen‑Caffier B, Schmidt S. Effects of open‑label placebos in clinical trials: a systematic review and meta‑analysis. Sci Rep . 2021;11:3855.
    By Mohamad-Ali Salloum, PharmD May 4, 2026
    References: Zaniletti I, Larson DR, Lewallen DG, Berry DJ, Maradit Kremers H. How to distinguish correlation from causation in orthopaedic research. J Arthroplasty. 2023;38(4):634–637. Rush J, Ajami M, Look KA, Margolis A. Statistics review part 10: causality and confounding. J Pharm Soc Wis. 2014;17(1):45–52. Koopmans E, Schiller C. Understanding causation in healthcare: an introduction to critical realism. Qual Health Res. 2022;32(8–9):1207–1214. Kahlert J, Gribsholt SB, Gammelager H, Dekkers OM, Luta G. Control of confounding in the analysis phase – an overview for clinicians. Clin Epidemiol. 2017;9:195–204. Shi AX, Zivich PN, Chu H. A comprehensive review and tutorial on confounding adjustment methods for estimating treatment effects using observational data. Appl Sci (Basel). 2024;14(9):3662. Gao Y, Xiang L, Yi H, Song J, Sun D, Xu B, et al. Confounder adjustment in observational studies investigating multiple risk factors: a methodological study. BMC Med. 2025;23:132. Ho FK, Brown J, Galwey NW. Regression adjustment for causal inference. BMJ Med. 2025;4:e000816. Correia LCL, Mascarenhas RF, Menezes FSC, Oliveira Junior JS, Vaccarino V, Ross JS, et al. Confounder selection in observational studies in high‑impact medical and epidemiological journals. JAMA Netw Open. 2025;8(7):e2524176.
    By Mohamad-Ali Salloum, PharmD May 1, 2026
    Explore the difference between Sensitivity and Specificity
    More Posts